论文部分内容阅读
肺动脉高压(pulmonary artery hypertension,PAH)是不同病因导致的、以肺动脉压力和肺血管阻力升高为特点的一组病理生理综合征。美国国立卫生研究院(national institutesof health,NIH)将 PAH 定义为:平均肺动脉压力在静息状态下大于25mm Hg(1mm Hg=0.133kPa),在运动状态下大于30mm Hg,而肺毛细血管压或者左心房压力小于15mm Hg。PAH 已经成为一个重要的医疗保健问题,NIH 对194例特发性 PAH 患者的统计,平均生存期仅为2.8年,1、3与5年的生存率分别为68%、48%和34%,与恶性肿瘤相仿。然而目前尚无根治的方法,病因和发病机制研究是实现有效防治的惟一途径,也是目前 PAH 研究的热点和难点。近年来在PAH 的发病机制研究方面取得的最重要的进展之一就是发
Pulmonary artery hypertension (PAH) is a group of pathophysiological syndromes characterized by various causes and characterized by elevated pulmonary artery pressure and pulmonary vascular resistance. The National Institutes of Health (NIH) defines PAH as: mean pulmonary artery pressure greater than 25 mm Hg (1 mm Hg = 0.133 kPa) at rest, greater than 30 mm Hg at rest, and pulmonary capillary pressure or Left atrial pressure less than 15mm Hg. PAH has become an important health care issue. The NIH’s statistics on 194 patients with idiopathic PAH mean an average survival of only 2.8 years. The 1,3 and 5-year survival rates were 68%, 48% and 34%, respectively. Similar to cancer. However, there is still no radical method, etiology and pathogenesis of the study is the only way to achieve effective prevention and treatment, but also the current PAH research hot and difficult. In recent years, one of the most important advances in the pathogenesis of PAH has been made